Having just caught up with the Earnings Call, I also note that Acadia has decided to drop the development program, licensed from Stoke Therapeutics, for an antisense therapy in Rett syndrome.
In January 2022, Acadia entered into a collaboration with Stoke Therapeutics. This was a co-development and co-commercialization agreement for a preclinical asset in SYNGAP1. It also included an exclusive license agreement for an asset for Rett syndrome as well as another undisclosed indication, both for which Acadia was to be responsible for clinical development and commercialization.
Acadia is now proceeding only with the SYNGAP1 asset.
Ann: DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024, page-35
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.04 |
Change
0.190(1.48%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.15 | $12.92 | $1.938M | 148.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 67 | $13.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.06 | 250 | 1 |
View Market Depth
| Last trade - 10.39am 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |